Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387121016> ?p ?o ?g. }
- W4387121016 endingPage "4759" @default.
- W4387121016 startingPage "4759" @default.
- W4387121016 abstract "Background: Mantle cell lymphoma (MCL) is a rare malignancy with heterogeneous behavior. Despite the therapeutic advances recently achieved, MCL remains incurable. Currently, the standard of care for young and fit patients involves induction immunochemotherapy followed by up-front autologous stem cell transplantation (ASCT). However, the role of more intensive induction regimens, such as those based on high doses of cytarabine (HDAC), remains controversial in the management of ASCT-eligible patients. Methods: This retrospective, observational, and single-center study involved 165 MCL patients treated at the largest oncology center in Latin America from 2010 to 2022. We aimed to assess outcomes, determine survival predictors, and compare responses between different primary therapeutic strategies, with a focus on assessing the impact of HDAC-based regimens on outcomes in ASCT-eligible patients. Results: The median age at diagnosis was 65 years (38–89 years), and 73.9% were male. More than 90% of the cases had a classic nodal form (cnMCL), 76.4% had BM infiltration, and 56.4% presented splenomegaly. Bulky ≥ 7 cm, B-symptoms, ECOG ≥ 2, and advanced-stage III/IV were observed in 32.7%, 64.8%, 32.1%, and 95.8%, respectively. Sixty-four percent of patients were categorized as having high-risk MIPI. With a median follow-up of 71.1 months, the estimated 2-year OS and EFS were 64.1% and 31.8%, respectively. Patients treated with (R)-HDAC-based regimens had a higher ORR (85.9% vs. 65.7%, p = 0.007) compared to those receiving (R)-CHOP, as well as lower POD-24 rates (61.9% vs. 80.4%, p = 0.043) and lower mortality (43.9% vs. 68.6%, p = 0.004). However, intensified induction regimens with (R)-HDAC were not associated with a real OS benefit in MCL patients undergoing up-front consolidation with ASCT (2-year OS: 88.7% vs. 78.8%, p = 0.289). Up-front ASCT was independently associated with increased OS (p < 0.001), EFS (p = 0.005), and lower POD-24 rates (p < 0.001) in MCL. Additionally, CNS infiltration, TLS, hypoalbuminemia, and the absence of remission after induction were predictors of poor OS. Conclusions: In the largest Latin American cohort of MCL patients, we confirmed the OS benefit promoted by up-front consolidation with ASCT in young and fit patients, regardless of the intensity of the immunochemotherapy regimen used in the pre-ASCT induction. Although HDAC-based regimens were not associated with an unequivocal increase in OS for ASCT-eligible patients, it was associated with higher ORR and lower rates of early relapses for the whole cohort." @default.
- W4387121016 created "2023-09-29" @default.
- W4387121016 creator A5003883532 @default.
- W4387121016 creator A5018201754 @default.
- W4387121016 creator A5036525714 @default.
- W4387121016 creator A5039392640 @default.
- W4387121016 creator A5040009342 @default.
- W4387121016 creator A5048717242 @default.
- W4387121016 creator A5049773753 @default.
- W4387121016 creator A5067611125 @default.
- W4387121016 creator A5090441276 @default.
- W4387121016 date "2023-09-28" @default.
- W4387121016 modified "2023-10-17" @default.
- W4387121016 title "Up-Front ASCT Overcomes the Survival Benefit Provided by HDAC-Based Induction Regimens in Mantle Cell Lymphoma: Data from a Real-Life and Long-Term Cohort" @default.
- W4387121016 cites W1549556227 @default.
- W4387121016 cites W1829587101 @default.
- W4387121016 cites W192358873 @default.
- W4387121016 cites W2012295982 @default.
- W4387121016 cites W2026122699 @default.
- W4387121016 cites W2056508494 @default.
- W4387121016 cites W2056952913 @default.
- W4387121016 cites W2059492063 @default.
- W4387121016 cites W2064323879 @default.
- W4387121016 cites W2082584333 @default.
- W4387121016 cites W2085346499 @default.
- W4387121016 cites W2093893201 @default.
- W4387121016 cites W2119147717 @default.
- W4387121016 cites W2124235514 @default.
- W4387121016 cites W2130669641 @default.
- W4387121016 cites W2137275043 @default.
- W4387121016 cites W2154066874 @default.
- W4387121016 cites W2156235279 @default.
- W4387121016 cites W2166319122 @default.
- W4387121016 cites W2189740376 @default.
- W4387121016 cites W2289178667 @default.
- W4387121016 cites W2310716991 @default.
- W4387121016 cites W2430862255 @default.
- W4387121016 cites W2470400696 @default.
- W4387121016 cites W2553488063 @default.
- W4387121016 cites W2598700764 @default.
- W4387121016 cites W2749289906 @default.
- W4387121016 cites W2760635695 @default.
- W4387121016 cites W2765433239 @default.
- W4387121016 cites W2774522106 @default.
- W4387121016 cites W2789664398 @default.
- W4387121016 cites W2900472144 @default.
- W4387121016 cites W2937620616 @default.
- W4387121016 cites W2939991989 @default.
- W4387121016 cites W3036344565 @default.
- W4387121016 cites W3149356036 @default.
- W4387121016 cites W3195905708 @default.
- W4387121016 cites W4220668131 @default.
- W4387121016 cites W4280496528 @default.
- W4387121016 cites W4281687647 @default.
- W4387121016 cites W4283381496 @default.
- W4387121016 cites W4283722059 @default.
- W4387121016 doi "https://doi.org/10.3390/cancers15194759" @default.
- W4387121016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37835453" @default.
- W4387121016 hasPublicationYear "2023" @default.
- W4387121016 type Work @default.
- W4387121016 citedByCount "0" @default.
- W4387121016 crossrefType "journal-article" @default.
- W4387121016 hasAuthorship W4387121016A5003883532 @default.
- W4387121016 hasAuthorship W4387121016A5018201754 @default.
- W4387121016 hasAuthorship W4387121016A5036525714 @default.
- W4387121016 hasAuthorship W4387121016A5039392640 @default.
- W4387121016 hasAuthorship W4387121016A5040009342 @default.
- W4387121016 hasAuthorship W4387121016A5048717242 @default.
- W4387121016 hasAuthorship W4387121016A5049773753 @default.
- W4387121016 hasAuthorship W4387121016A5067611125 @default.
- W4387121016 hasAuthorship W4387121016A5090441276 @default.
- W4387121016 hasBestOaLocation W43871210161 @default.
- W4387121016 hasConcept C126322002 @default.
- W4387121016 hasConcept C141071460 @default.
- W4387121016 hasConcept C143998085 @default.
- W4387121016 hasConcept C197934379 @default.
- W4387121016 hasConcept C2776694085 @default.
- W4387121016 hasConcept C2777525834 @default.
- W4387121016 hasConcept C2778041864 @default.
- W4387121016 hasConcept C2778375690 @default.
- W4387121016 hasConcept C2779050716 @default.
- W4387121016 hasConcept C2779338263 @default.
- W4387121016 hasConcept C2779399171 @default.
- W4387121016 hasConcept C71924100 @default.
- W4387121016 hasConcept C72563966 @default.
- W4387121016 hasConceptScore W4387121016C126322002 @default.
- W4387121016 hasConceptScore W4387121016C141071460 @default.
- W4387121016 hasConceptScore W4387121016C143998085 @default.
- W4387121016 hasConceptScore W4387121016C197934379 @default.
- W4387121016 hasConceptScore W4387121016C2776694085 @default.
- W4387121016 hasConceptScore W4387121016C2777525834 @default.
- W4387121016 hasConceptScore W4387121016C2778041864 @default.
- W4387121016 hasConceptScore W4387121016C2778375690 @default.
- W4387121016 hasConceptScore W4387121016C2779050716 @default.
- W4387121016 hasConceptScore W4387121016C2779338263 @default.
- W4387121016 hasConceptScore W4387121016C2779399171 @default.
- W4387121016 hasConceptScore W4387121016C71924100 @default.
- W4387121016 hasConceptScore W4387121016C72563966 @default.